- UroToday Home
- Urologic Oncology
The Latest Bladder Cancer Research
Recent Abstracts
-
Targeted Sequencing of Non-schistosomal Squamous Cell Carcinoma of the Urinary Bladder – Expert CommentaryBladder CancerJanuary 20, 2022
-
Culture of Bladder Cancer Organoids as Precision Medicine Tools.Bladder CancerJanuary 20, 2022
-
Gene network profiling in muscle-invasive bladder cancer: A systematic review and meta-analysis.Bladder CancerJanuary 20, 2022
-
Recirculating hyperthermic intravesical chemotherapy with mitomycin C (HIVEC) versus BCG in high-risk non-muscle-invasive bladder cancer: results of the HIVEC-HR randomized clinical trial.Bladder CancerJanuary 19, 2022
-
Bladder cancer in patients with neurogenic bladder disorder: a comparative study of different etiologies.Bladder CancerJanuary 19, 2022
-
Genomic characterization of non-schistosomiasis-related squamous cell carcinoma of the urinary bladder: A retrospective exploratory study.Bladder CancerJanuary 19, 2022
-
Residual CIS after Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle Invasive Bladder Cancer: Implications for Neoadjuvant TrialsBladder CancerJanuary 18, 2022
-
Renal Morbidity Following Radical Cystectomy in Patients with Bladder Cancer.Bladder CancerJanuary 18, 2022
-
Modified 5-Item Frailty Index Score as Prognostic Marker After Radical Cystectomy in Bladder Cancer.Bladder CancerJanuary 18, 2022
-
Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study.Bladder CancerJanuary 17, 2022
Beyond the Abstracts
-
Updated European Association of Urology (EAU) Prognostic Factor Risk Groups Overestimate the Risk of Progression in Patients with Non-muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guérin - Beyond the AbstractBladder CancerJanuary 19, 2022
-
Oncofid-P-B for High Risk NMIBC: Do We Really Need a Phase III? Yes, We Do - Beyond the AbstractBladder CancerJanuary 18, 2022
-
Analysis of Open Chromatin Regions in Bladder Cancer Links β-Catenin Mutations and Wnt Signaling with Neuronal Subtype of Bladder Cancer - Beyond the AbstractBladder CancerJanuary 10, 2022
-
Underutilization of Blue Light Cystoscopy for Bladder Cancer in the United States - Beyond the AbstractBladder CancerNovember 15, 2021
-
Utility of Stromal Tumor Infiltrating Lymphocyte Scoring (sTILs) for Risk Stratification of Patients with Muscle-Invasive Urothelial Bladder Cancer After Radical Cystectomy - Beyond the AbstractBladder CancerNovember 9, 2021
-
Role of Local Therapy in Clinical Node-Positive Bladder Cancer - Beyond the AbstractBladder CancerNovember 8, 2021
-
Association of Age with Response to Preoperative Chemotherapy in Patients with Muscle-Invasive Bladder Cancer - Beyond the AbstractBladder CancerNovember 2, 2021
-
Society for Immunotherapy of Cancer (SITC) Clinical Practice Guideline on Immunotherapy for the Treatment of Urothelial Cancer - Beyond the AbstractBladder CancerOctober 12, 2021
-
Vaginal Complications after Radical Cystectomy for Bladder Cancer: A Systematic Review - Beyond the AbstractBladder CancerOctober 11, 2021
-
Role of Ki-67, MRE11, and PD-L1 as Predictive Biomarkers for Recurrence Pattern in Muscle-invasive Bladder Cancer - Beyond the AbstractBladder CancerOctober 11, 2021
